Loading...

Olema Pharmaceuticals ($OLMA)

OLMA Overview

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers.Its lead program is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer.The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. (From: StockAnalysis.com)

MORE ABOUT Olema Pharmaceuticals

Stay up to date with the best of Bullish each week.

BULLISH WEEKLY

Stay up to date with the best of Bullish each week.